Literature DB >> 16527424

The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus.

K A Takahashi1, P E Castillo.   

Abstract

Cannabinoids have profound effects on synaptic function and behavior. Of the two cloned cannabinoid receptors, cannabinoid receptor 1 (CB1) is widely distributed in the CNS and accounts for most of the neurological effects of cannabinoids, while cannabinoid receptor 2 (CB2) expression in the CNS is very limited. The presence of additional receptors [i.e. cannabinoid receptor 3 (CB3)] is suggested by growing evidence of cannabinoid effects that are not mediated by CB1 or CB2. The most direct functional evidence for a CB3 comes from a study in hippocampus where deletion of CB1 was shown to have no effect on cannabinoid-mediated suppression of the excitatory synapse between Schaffer collateral/commissural fibers and CA1 pyramidal cells [Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4]. In contrast, we report here that in extracellular field recordings, the cannabinoid agonist WIN 55,212-2 (5 microM) had no effect on Schaffer collateral/commissural fiber-CA1 pyramidal cell (Sch-CA1) synaptic transmission in slices from two independently made cannabinoid receptor 1-/- lines [Zimmer et al 1999 and Ledent et al 1999] while strongly suppressing Sch-CA1 synaptic transmission in CB1+/+ mice of the background strains. Also, we observed robust cannabinoid-mediated suppression of the Sch-CA1 synapse in pure C57BL/6 mice, contradicting a recent report that cannabinoid suppression of this synapse is absent in this strain [Hoffman AF, Macgill AM, Smith D, Oz M, Lupica CR (2005) Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci 22:2387-2391]. Our results strongly suggest that cannabinoid-induced suppression of the Sch-CA1 synapse is mediated by CB1. Non-canonical cannabinoid receptors do not seem to play a major role in inhibiting transmitter release at this synapse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527424     DOI: 10.1016/j.neuroscience.2006.01.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  56 in total

1.  Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex.

Authors:  Chiayu Q Chiu; Nagore Puente; Pedro Grandes; Pablo E Castillo
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

3.  Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Authors:  Alexander F Hoffman; Murat Oz; Ruiqin Yang; Aron H Lichtman; Carl R Lupica
Journal:  Learn Mem       Date:  2007-01-03       Impact factor: 2.460

4.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

5.  TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons.

Authors:  Helen E Gibson; Jeffrey G Edwards; Rachel S Page; Matthew J Van Hook; Julie A Kauer
Journal:  Neuron       Date:  2008-03-13       Impact factor: 17.173

Review 6.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

7.  Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands.

Authors:  Michal Bajo; Marisa Roberto; Paul Schweitzer
Journal:  J Neurosci Res       Date:  2009-02-15       Impact factor: 4.164

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 9.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway.

Authors:  Giuseppe Tortoriello; Claudia V Morris; Alan Alpar; Janos Fuzik; Sally L Shirran; Daniela Calvigioni; Erik Keimpema; Catherine H Botting; Kirstin Reinecke; Thomas Herdegen; Michael Courtney; Yasmin L Hurd; Tibor Harkany
Journal:  EMBO J       Date:  2014-01-27       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.